發炎性腸病治療藥市場

發炎性腸病治療藥市場 是由出版商Austin Research Analytics Group在2007年03月所出版的。 這份英文市場調查報告書包含134 Pages 價格從美金1550起跳。

目錄

Abstract

In 2007, Remicade (infliximab/Anti-TNF-?), the current market leader in the treatment of moderate-to-severe Crohn' s Disease (CD), is expected to experience fierce challenges for patient share from 2-3 new Anti-TNF class competitors; Humira, Tysabri,Cimzia. Humira (adalimumab) was approved in January 2007 for CD and will compete with Remicade based upon relative efficacy & convenience (Pen Injector); while despite the fact that Tysabri' s (natalizumab/VLA-4) safety will dampen initial uptake, the product' s novel mechanism and efficacy could enable it to capture share within the more severe patient segment. Cimzia' s (certolizumab pegol) 2007 planned launch may be postponed due to FDA regulatory delays, forcing UCB Pharma to conduct an additional study-and making a 2008 launch much more plausible.

Similarly, the competitive landscape for Ulcerative Colitis (UC) treatments has the potential to shift over the next 2-4 years as more products are undergoing late-phase clinical trials in an attempt to maximize exposure in the IBD therapeutic area and garner share from UC market-leader Remicade. In particular, competitive threats to Remicade may come from programs including; Humira & Orencia recently initiated large phase III studies in moderate-to-severe UC, Tysabri is expected to commence trials in UC in 2007, and novel pipeline programs such as Nuvion (visilizumab) continue to progress.

The scope of this report will concentrate on the Research & Development (R&D) competitive landscape for moderate-to-severe CD & UC therapeutics. The focus of the intelligence is on the clinical elements of competitive products from a clinical perspective; which provides insight into the strategic opportunities and challenges facing drug developers and marketers. Specifically, the focus of our analysis is on the clincial trial protocol designs and data results for 15 compounds in phase II or beyond that have the potential to alter the market dynamics in IBD over the next 5-7 years.

Table of Contents

• Scope of Assessment
• Overview of Competitive Landscape for IBD
• Products Profiled in IBD Clinical Intelligence Report
• Snap-Shot of Ongoing Clinical Trials in Crohn' s Disease and Ulcerative Colitis
• Ongoing Clinical Trials-Key Players in IBD
• Key Competitor Product Profiles
• Key Competitor Filing and Approval Timeline
• Overview of Key Competitor Pivotal Trial Designs
• Analysis of Study Time-to-Complete & Number of Patients for Pivotal Trials in Crohn' s Disease

• Product Overview- Competitor Snapshot
• Remicade' s Path-to-Market & Development Timeline
• Remicade (Infliximab) Crohn' s Disease
  • Phase I Study: Design & Results Overview
  • Phase II (Study T11): Design & Results Overview
  • Phase II Study Design (T16)
  • Phase II Study Design (T16)-Continued
  • Phase II Study Results (T16)
  • Phase II Study Results (T16): Open Label Analysis
  • Remicade Phase III Trial Design (ACCENT-1)
  • Remicade Phase III Trial Results (ACCENT-1)
  • Phase III Trial Design (ACCENT-2)
• Remicade Phase III Trial Results (ACCENT-2)
  • Remicade Study Design in Pediatric Patients Crohn' s Disease
  • Remicade Study Results in Pediatric Patients with Crohn' s Disease
  • Ongoing Studies Industry-sponsored with Remicade Clinical in Crohn' s Disease
  • Ongoing Studies Industry-sponsored with Remicade in Crohn' s Disease
  • Remicade (Infliximab) Ulcerative Colitis
  • Phase III Trial Design (ACT-1 & ACT-2)
  • Phase III Trial Results (ACT-1)
  • Phase III Trial Results (ACT-2)
  • Phase III Trial Results (ACT-1 & ACT-2)
  • Ongoing Studies with Remicade in Ulcerative Colitis

• Humira (Adalimumab) Crohn' s Disease
  • Humira Product Overview- Competitor Snapshot
  • Phase II Study Design and Results
  • Phase II Study Design
  • Phase II Study Results
  • Phase II Study Design & Results
  • Phase III Study Design (CHARM)
  • Phase III Study Results (CHARM)
  • Phase III Study Design (CLASSIC I & II)
  • Phase III Study Results (CLASSIC-1 & CLASSIC-2)
  • Phase III Study Results (CLASSIC-2)
  • Phase III Study Design (GAIN)
  • Phase III Study Results (GAIN)
  • Ongoing Studies in Crohn' s Disease
  • Ongoing Phase III Study in Crohn' s Disease
• Humira (Adalimumab) Ulcerative Colitis
  • Phase II/III Ongoing Study
• Cimzia (certolizumab) Crohn' s Disease
  • Product Overview: Competitor Snapshot
  • Phase III Study Design (PRECiSE 1&2)
  • Phase III Study Results (PRECiSE 1&2)
  • Ongoing Studies in Crohn' s Disease
• Tysabri (natalizumab) Crohn' s Disease
  • Product Overview- Competitor Snapshot
  • Phase II Study Design
  • Phase II Study Results
  • Phase III Study Design (ENACT-1)
  • Phase III Study Results (ENACT-1)
  • Phase III Study Design (ENACT-2)
  • Phase III Study Results (ENACT-2)
  • Phase III Study Design (ENCORE)
  • Phase III Study Results (ENCORE)
• Orencia (abatacept) Crohn' s Disease
  • Orencia Product Overview: Competitor Snapshot
  • Orencia Phase III Study Design
• Orencia (abatacept) Ulcerative Colitis
  • Orencia Phase III Study Design
• Nuvion (Visilizumab) Ulcerative Colitis
  • Nuvion Product Overview: Competitor Snapshot
  • Nuvion Phase I/II Study Design & Results
  • Nuvion Ongoing Phase II/III Study in Ulcerative Colitis
  • Nuvion Ongoing Studies in Ulcerative Colitis

• Rituxan (rituximab) Ulcerative Colitis
  • Rituxan: Product Overview: Competitor Snapshot
  • Rituxan Phase II/III Ongoing Study Design
• ABT-874 Crohn' s Disease
  • ABT-874 Product Overview: Competitor Snapshot
  • ABT-874 Phase II Study Design
  • ABT-874 Phase II Study Results
• MLN-02 Ulcerative Colitis
  • MLN02: Product Overview- Competitor Snapshot
  • MLN-02 Phase II Study Design
  • MLN-02 Phase II Study Results
• Traficet-EN (CCX282-B) Crohn' s Disease
  • Traficet-EN Product Overview-Competitor Snapshot
  • Traficet-EN Phase II Study Design
  • Traficet-EN Phase II Study Results
  • Traficet-EN Ongoing Study in Crohn' s Disease
• Firategrast (683699) Crohn' s Disease
  • Firategrast Product Overview: Competitor Snapshot
  • Firategrast Phase II Study Design
• MDX-1100 Crohn' s Disease
  • MDX-1100 Product Overview: Competitor Snapshot
  • MDX-1100 Ongoing Study in Crohn' s Disease
  • MDX-1100 Ongoing Study in Crohn' s Disease (con' t)

• AZD-9056 IBD (Undisclosed)
  • AZD-9056 Product Overview: Competitor Snapshot
  • AZD-9056 Ongoing Study (POPCORN)
• Semapimod (CNI-1493) Crohn' s Disease
  • Semapimod Product Overview: Competitor Snapshot
  • Semapimod (CNI-1493) Clinical Trials:
• RDP-58 127
  • RDP58 Product Overview: Competitor Snapshot
  • RDP-58 Phase II Clinical Trial Design & Results- Ulcerative Colitis

• References
• References (Continued)
• Disclaimer
• Report Licensing

• Figure 1: Overview of IBD Competitive Landscape
• Figure 2: Snap-Shot of Ongoing Clinical Trials in IBD
• Figure 3: Ongoing Studies of Key Players in IBD
• Figure 4: Key Competitor Filings & Approval Timeline
• Figure 5: Analysis of Study Time-to-Complete for Pivotal Trials in Crohn' s Disease
• Figure 6: Trial Sizes- Total Number of Patients in Pivotal Studies

• Table 1: Products Profiled in the Report
• Table 2: Key Competitor Product Profiles
• Table 3: Overview of Key Competitor Pivotal Trial Designs

相關商品

Austin Research Analytics Group發行的製藥相關市場調查報告書

風濕性關節炎治療藥市場

Therapeutic Clinical Intelligence: Rheumatoid Arthritis

價格 : US $ 2300

出版日期 : 2009年01月

治療藥的臨床智慧：多發性硬化症（Vol.2）

Therapeutic Clinical Intelligence - Multiple Sclerosis Volume II

價格 : US $ 2250

出版日期 : 2007年10月

多發性硬化症治療藥

Therapeutic Clinical Intelligence-Multiple Sclerosis

價格 : US $ 2050

出版日期 : 2007年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!